top of page
The Sound of Evolution
Obinutuzumab
Mechanism of action:
Obinutuzumab is a second-generation anti-CD20 IgG1 monoclonal antibody. The target of obinutuzumab is the CD20 antigen on the surface of B cells. Obinutuzumab is designed with high affinity of its Fc region for the FcγRIIIa (CD16) receptor. After obinutuzumab binds to B cell-related malignancies, it promotes cytotoxic activity mediated by natural killer cells and macrophages.
Reference(s):
1. Owen C et al. (2012). Obinutuzumab for the treatment of lymphoproliferative disorders. Expert Opin Biol Ther.
2. Cartron G et al. (2017). Obinutuzumab: what is there to learn from clinical trials? Blood.
3. Davies A et al. (2022). Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review. Future Oncol.
bottom of page